Abstract: The present invention concerns a method for the preparation of therapeutically valuable triphenylbutene derivatives, especially ospemifene or fispemifene.

Abstract: The present invention concerns a method for the preparation of therapeutically valuable triphenylbutene derivatives, especially ospemifene or fispemifene.

Abstract: The present invention concerns a method for the preparation of therapeutically valuable triphenylbutene derivatives, especially ospemifene or fispemifene.

Abstract: Novel phenolic esters of lignans, and pharmaceutical compositions, dietary supplements, and food products containing these esters.

Abstract: The present invention concerns a method for preparation of fispemifene by use of ospemifene as a starting material.

Abstract: The present invention concerns a method for preparation of fispemifene by use of ospemifene as a starting material.

Abstract: The present invention concerns a method for the preparation of therapeutically valuable triphenylbutene derivatives, especially ospemifene or fispemifene.

Abstract: A method for the production of hydroxymatairesinol or a hydroxymatairesinol complex from wood, including the steps of a) extracting finely divided wood material with a polar solvent, b) optionally concentrating the extract by separating at least part of the solvent, c) adding to the extract an agent able to form a complex with hydroxymatairesinol, d) precipitating the hydroxymatairesinol complex, and optionally e) releasing the hydroxymatairesinol from the complex.

Abstract: Novel phenolic esters of lignans, and pharmaceutical compositions, dietary supplements, and food products containing these esters.

Abstract: A new method for the preparation of a selective estrogen receptor modulator and its isomers. Also disclosed is the preparation of new intermediates and their use in the preparation of the selective estrogen receptor modulator.

Abstract: A method for the preparation of matairesinol from hydroxymatairesinol, either by (i) catalytic hydrogenolysis of the hydroxy group in 7-position of hydroxymatairesinol, where the reaction is carried out in a suitable solvent as a pressurized hydrogenolysis, or (ii) reduction of hydroxymatairesinol, where the reduction is carried out as a hydrogen transfer reaction from a hydrogen donor in the presence of a catalyst.

Abstract: The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2, which are the same or different are a) H, halogen, OCH3, OH; or where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, —CH2C?CH or —CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or c) —Y—(CH2)nCH2—O—R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, —CH2CH2OH, or —CH2CH2Cl; or d) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and ?R3 is H, halogen, OH or —OCH3; stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.

Abstract: This invention concerns a method for the production of hydroxymatairesinol or a hydroxymatairesinol complex from wood, comprising the steps of

Abstract: This invention relates to a new method for the preparation of a selective estrogen receptor modulator and its isomers. The invention concerns also new intermediates prepared and further used in said method.

Abstract: The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2 , which are the same or different are a) H, halogen, OCH3, OH; or where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, —CH2C≡CH or —CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or c) —Y—(CH2)nCH2—O—R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, —CH2CH2OH, or —CH2CH2Cl; or d) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or —OCH3; stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.

Abstract: The invention provides novel selective estrogen receptor modulator compounds of the general formula: 1

Abstract: The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2, which are the same or different are a) H, halogen, OCH3, OH; or  where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, —CH2C≡CH or —CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or c) —Y—(CH2)nCH2—O—R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, —CH2CH2OH, or —CH2CH2Cl; or d) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or —OCH3; stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.

Abstract: The present invention relates to E-2-[4-(chloro-1,2-diphenyl-butleny1)phenoxy]ethanol which is useful in lowering serum cholesterol and to pharmaceutical compositions thereof. The invention also describes methods of lowering serum cholesterol and methods for the prevention of or the treatment of atherosclerosis.

Abstract: The invention provides novel compounds of the formula: ##STR1## wherein R.sub.1 and R.sub.2, which can be the same or different are H or OH, R.sub.3 is ##STR2## wherein R.sub.4 and R.sub.5, which can be the same or different are H or an alkyl group of 1 to 4 carbon atoms, and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds include metabolites of toremifene and exhibit valuable pharmacological properties as oestrogenic, anti-oestrogenic, and progestanic agents.